Strong Predictive Value of Organoid-Based PARIS® Test to Identify Personalized Treatments in Advanced Cancers Presented at 2021 ASCO Annual Meeting
SEATTLE, June 08, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived tumor organoids employing its CLIA-certified PARIS® Test, today presented new data from a study summarizing the predictive value of the PARIS® Test across solid tumors during a poster session (abstract 2602) at the American Society of Clinical Oncology annual meeting, to be held virtually June 4-8, 2021.
The study underscored the strong correlation between treatment outcomes and PARIS® Test results based on an analysis of a 419-patient pan-cancer cohort, mostly in the metastatic setting. Data presented in this study complemented initial findings presented at the 2020 ASCO annual meeting (abstract 3630). Notably, the current study introduced data on clinical outcome predictions based on the results of the PARIS® Test. Study authors also found concordance between PARIS® Test drug responses and known genomic biomarkers, such as KRASG12 mutation and MEK inhibitors. Investigators concluded that PARIS® Test results have a strong correlation with patients’ clinical outcomes in 71.7% of the post-PARIS® Test treated group.
“This study presents for the first time a clos correlation between PARIS® Test results and prospective clinical outcomes,” said Astrid Margossian, MD, PhD, Chief Medical Officer at SEngine Precision Medicine. “Adoption of the PARIS® Test in clinic has accelerated over the past year, helping the oncologist in treatment decisions in 62.3% of cases. Moreover, the strong predictive value of the PARIS® Test provides treating oncologists with a tool to identify personalized therapeutic options to a given patient’s cancer.”
Details related to the poster presentation are as follows:
About PARIS® Test
About SEngine Precision Medicine
Session Details Coming Soon
Conference Sessions (Full conference pass required)